309 related articles for article (PubMed ID: 14998494)
1. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma.
Hurt EM; Wiestner A; Rosenwald A; Shaffer AL; Campo E; Grogan T; Bergsagel PL; Kuehl WM; Staudt LM
Cancer Cell; 2004 Feb; 5(2):191-9. PubMed ID: 14998494
[TBL] [Abstract][Full Text] [Related]
2. c-maf in multiple myeloma: an oncogene enhancing tumor-stroma interactions.
Kienast J; Berdel WE
Cancer Cell; 2004 Feb; 5(2):109-10. PubMed ID: 14998484
[TBL] [Abstract][Full Text] [Related]
3. TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines.
Moreaux J; Hose D; Jourdan M; Reme T; Hundemer M; Moos M; Robert N; Moine P; De Vos J; Goldschmidt H; Klein B
Haematologica; 2007 Jun; 92(6):803-11. PubMed ID: 17550853
[TBL] [Abstract][Full Text] [Related]
4. CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells.
Tai YT; Soydan E; Song W; Fulciniti M; Kim K; Hong F; Li XF; Burger P; Rumizen MJ; Nahar S; Podar K; Hideshima T; Munshi NC; Tonon G; Carrasco RD; Afar DE; Anderson KC
Blood; 2009 Apr; 113(18):4309-18. PubMed ID: 19196658
[TBL] [Abstract][Full Text] [Related]
5. C-MAF oncogene dysregulation in multiple myeloma: frequency and biological relevance.
Rasmussen T; Knudsen LM; Dahl IM; Johnsen HE
Leuk Lymphoma; 2003 Oct; 44(10):1761-6. PubMed ID: 14692531
[TBL] [Abstract][Full Text] [Related]
6. Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion.
Neri P; Ren L; Azab AK; Brentnall M; Gratton K; Klimowicz AC; Lin C; Duggan P; Tassone P; Mansoor A; Stewart DA; Boise LH; Ghobrial IM; Bahlis NJ
Blood; 2011 Jun; 117(23):6202-13. PubMed ID: 21474670
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of c-Maf contributes to T-cell lymphoma in both mice and human.
Morito N; Yoh K; Fujioka Y; Nakano T; Shimohata H; Hashimoto Y; Yamada A; Maeda A; Matsuno F; Hata H; Suzuki A; Imagawa S; Mitsuya H; Esumi H; Koyama A; Yamamoto M; Mori N; Takahashi S
Cancer Res; 2006 Jan; 66(2):812-9. PubMed ID: 16424013
[TBL] [Abstract][Full Text] [Related]
8. Protein Expression for Novel Prognostic Markers (Cyclins D1, D2, D3, B1, B2, ITGβ7, FGFR3, PAX5) Correlate With Previously Reported Gene Expression Profile Patterns in Plasma Cell Myeloma.
Mansoor A; Akhter A; Pournazari P; Mahe E; Shariff S; Farooq F; Elyamany G; Shahbani-Rad MT; Rashid-Kolvear F
Appl Immunohistochem Mol Morphol; 2015; 23(5):327-33. PubMed ID: 25265432
[TBL] [Abstract][Full Text] [Related]
9. The ubiquitin-conjugating enzyme UBE2O modulates c-Maf stability and induces myeloma cell apoptosis.
Xu Y; Zhang Z; Li J; Tong J; Cao B; Taylor P; Tang X; Wu D; Moran MF; Zeng Y; Mao X
J Hematol Oncol; 2017 Jul; 10(1):132. PubMed ID: 28673317
[TBL] [Abstract][Full Text] [Related]
10. Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma.
Alvarez-Benayas J; Trasanidis N; Katsarou A; Ponnusamy K; Chaidos A; May PC; Xiao X; Bua M; Atta M; Roberts IAG; Auner HW; Hatjiharissi E; Papaioannou M; Caputo VS; Sudbery IM; Karadimitris A
Nat Commun; 2021 Sep; 12(1):5450. PubMed ID: 34521827
[TBL] [Abstract][Full Text] [Related]
11. Identification of small compounds that inhibit multiple myeloma proliferation by targeting c-Maf transcriptional activity.
Asano K; Kikuchi K; Takehara M; Ogasawara M; Yoshioka Y; Ohnishi K; Iwata A; Shimizu S; Tanaka M
Biochem Biophys Res Commun; 2023 Dec; 684():149135. PubMed ID: 37879249
[TBL] [Abstract][Full Text] [Related]
12. A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin.
Mao X; Stewart AK; Hurren R; Datti A; Zhu X; Zhu Y; Shi C; Lee K; Tiedemann R; Eberhard Y; Trudel S; Liang S; Corey SJ; Gillis LC; Barber DL; Wrana JL; Ezzat S; Schimmer AD
Blood; 2007 Dec; 110(12):4047-54. PubMed ID: 17875808
[TBL] [Abstract][Full Text] [Related]
13. Targeting the oncogenic transcription factor c-Maf for the treatment of multiple myeloma.
Jiang Q; Mao H; He G; Mao X
Cancer Lett; 2022 Sep; 543():215791. PubMed ID: 35700821
[TBL] [Abstract][Full Text] [Related]
14. Adhesive interactions between tumour cells and bone marrow stromal elements in human multiple myeloma.
Faid L; Van Riet I; De Waele M; Facon T; Schots R; Lacor P; Van Camp B
Eur J Haematol; 1996 Nov; 57(5):349-58. PubMed ID: 9003475
[TBL] [Abstract][Full Text] [Related]
15. Long non-coding RNA ANGPTL1-3 promotes multiple myeloma bortezomib resistance by sponging miR-30a-3p to activate c-Maf expression.
Nian F; Zhu J; Chang H
Biochem Biophys Res Commun; 2019 Jul; 514(4):1140-1146. PubMed ID: 31103265
[TBL] [Abstract][Full Text] [Related]
16. Expression of adhesion molecules in malignant plasma cells in multiple myeloma: comparison with normal plasma cells and functional significance.
Helfrich MH; Livingston E; Franklin IM; Soutar RL
Blood Rev; 1997 Mar; 11(1):28-38. PubMed ID: 9218104
[TBL] [Abstract][Full Text] [Related]
17. Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment.
Corso A; Ferretti E; Lazzarino M
Hematology; 2005 Jun; 10(3):215-24. PubMed ID: 16019470
[TBL] [Abstract][Full Text] [Related]
18. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.
Nguyen AN; Stebbins EG; Henson M; O'Young G; Choi SJ; Quon D; Damm D; Reddy M; Ma JY; Haghnazari E; Kapoun AM; Medicherla S; Protter A; Schreiner GF; Kurihara N; Anderson J; Roodman GD; Navas TA; Higgins LS
Exp Cell Res; 2006 Jun; 312(10):1909-23. PubMed ID: 16600214
[TBL] [Abstract][Full Text] [Related]
19. Sphingosine-1-phosphate activates chemokine-promoted myeloma cell adhesion and migration involving α4β1 integrin function.
García-Bernal D; Redondo-Muñoz J; Dios-Esponera A; Chèvre R; Bailón E; Garayoa M; Arellano-Sánchez N; Gutierrez NC; Hidalgo A; García-Pardo A; Teixidó J
J Pathol; 2013 Jan; 229(1):36-48. PubMed ID: 22711564
[TBL] [Abstract][Full Text] [Related]
20. Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma.
Bergsagel PL; Kuehl WM
Immunol Rev; 2003 Aug; 194():96-104. PubMed ID: 12846810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
